AR074596A1 - Derivados de (3-oxo) piridazin-4-ilurea - Google Patents

Derivados de (3-oxo) piridazin-4-ilurea

Info

Publication number
AR074596A1
AR074596A1 ARP090104810A ARP090104810A AR074596A1 AR 074596 A1 AR074596 A1 AR 074596A1 AR P090104810 A ARP090104810 A AR P090104810A AR P090104810 A ARP090104810 A AR P090104810A AR 074596 A1 AR074596 A1 AR 074596A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
monocyclic
groups
optionally substituted
Prior art date
Application number
ARP090104810A
Other languages
English (en)
Inventor
Gomez Sara Sevilla
Moll Joan Taltavull
Albero Maria Antonia Buil
Ferrer Jordi Gracia
Santacana Lluis Miquel Pages
Mollo Inmaculada Montserrat Moreno
Roberts Richard Spurring
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR074596A1 publication Critical patent/AR074596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen derivados de (3-oxo)piridazin-4-ilurea que tienen la estructura de fórmula (1); así como composiciones farmacéuticas que los comprenden y su uso en terapia como inhibidores de la fosfodiesterasa IV (PDE4). Reivindicación 1: Un compuesto de fórmula (1) donde R1 se selecciona del grupo que consiste en un grupo -alquil C1-4-cicloalquilo C3-5 y un grupo C1-4 opcionalmente sustituido con uno o más átomos de halógeno, R2 se selecciona del grupo que consiste en un grupo arilo C5-10, y un grupo heteroarilo de 5 a 10 miembros que contiene al menos un heteroátomo seleccionado de N, S y O, donde los grupos arilo y heteroarilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4 y alcoxi C1-4, X se selecciona del grupo que consiste en un enlace directo, -O-, -O-CH2-, -S-, y -S(O)2-, G1 se selecciona del grupo que consiste en un átomo de nitrógeno y un grupo -CH=, G2 se selecciona del grupo que consiste en un átomo de nitrógeno y un grupo -CR3=, R3 y R4 independientemente se seleccionan del grupo que consiste en un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxi, un grupo ciano, un grupo alquilo C1-4 lineal o ramificado, un grupo hidroxialquilo C1-4 lineal o ramificado, un grupo metilsulfonilo, sulfoniloxi, trifluorometilo, trifluorometoxi, ciclopropiloxi, un grupo formilo, un grupo -CH2N(CH3)2, -O-(CH2)1-3-Rb, -O-(CH2)1-5NRaRb, -(CH2)0-4-C(O)ORb, -(CH2)0-4C(O)NRaRb, -(CH2)0-2-CO-NH-(CH2)1-3-Rb y -(CH2)0-2-CO-NH-(CH2)1-8-NRaRb donde Ra representa un átomo de hidrógeno o un grupo alquilo C1-4, Rb representa un átomo de hidrógeno, un grupo alquilo C1-4, carboxialquilo C1-4, hidroxialquilo C1-2, carbamoílo, cicloalquilo C3-10 monocíclico o policíclico, carbocíclico C3-10 no aromático insaturado monocíclico o policíclico, un grupo arilo C5-10 monocíclico o policíclico, heteroarilo de 5 a 10 miembros monocíclico o policíclico, o un grupo heterocíclico de 5 a 10 miembros monocíclico o policíclico, grupos cicloalquilo, carbocíclico no aromático insaturado, arilo, heteroarilo y heterocíclico que están opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo que consiste en átomos de halógeno, grupos hidroxi, bencilo, alquilo C1-2, hidroxialquilo C1-6, dialquilamino C1-4 o grupos carboxi, o Ra y Rb junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico saturado o insaturado de 4 a 6 miembros que contiene opcionalmente un heteroátomo adicional seleccionado de N y O, y opcionalmente sustituido con un grupo alquilo C1-4, carbamoilo o un grupo alcoxi C1-2-alquilo C1-2; n es un número entero de 1 a 3 o sus sales y N-óxidos farmacéuticamente aceptables.
ARP090104810A 2008-12-15 2009-12-11 Derivados de (3-oxo) piridazin-4-ilurea AR074596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382077A EP2196465A1 (en) 2008-12-15 2008-12-15 (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

Publications (1)

Publication Number Publication Date
AR074596A1 true AR074596A1 (es) 2011-01-26

Family

ID=40404496

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104810A AR074596A1 (es) 2008-12-15 2009-12-11 Derivados de (3-oxo) piridazin-4-ilurea

Country Status (5)

Country Link
EP (1) EP2196465A1 (es)
AR (1) AR074596A1 (es)
TW (1) TW201026681A (es)
UY (1) UY32239A (es)
WO (1) WO2010069504A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA113750C2 (xx) * 2011-12-27 2017-03-10 Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
KR20150023722A (ko) * 2012-06-12 2015-03-05 애브비 인코포레이티드 피리디논 및 피리다지논 유도체
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
LT2931275T (lt) 2012-12-17 2022-06-27 Almirall S.A. Aklidiniumas, skirtas naudoti fizinio aktyvumo kasdieniniame gyvenime padidinimui pacientui, sergančiam lėtine obstrukcine plaučių liga
AP2015008573A0 (en) 2012-12-18 2015-07-31 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonsit activity
MX2015007921A (es) * 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
WO2015058160A1 (en) 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
CN103664770A (zh) * 2013-12-06 2014-03-26 辽宁师范大学 5-[2-(5-羧基-吡啶基)]-1,3-苯二羧酸的合成方法
CN103664796A (zh) * 2013-12-06 2014-03-26 辽宁师范大学 5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
WO2016139361A1 (en) 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017070708A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3442972B1 (en) 2016-04-15 2020-03-04 AbbVie Inc. Bromodomain inhibitors
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2019250361B2 (en) 2018-04-12 2023-03-23 Bayer Aktiengesellschaft Heteroaryl-triazole compounds as pesticides
CA3102762A1 (en) 2018-06-04 2019-12-12 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
TWI817191B (zh) 2020-09-04 2023-10-01 南韓商Ｌｇ化學股份有限公司 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9204808D0 (en) 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
JP3195353B2 (ja) 1992-04-02 2001-08-06 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
US5829434A (en) 1992-12-18 1998-11-03 Schering Corporation Inhaler for powdered medications
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
WO1996040636A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. Catechol diethers derivatives useful as pharmaceutical agents
PL182198B1 (en) 1995-06-21 2001-11-30 Asta Medica Ag Pharmaceutic powder holding container with integrated measuring device and powdered
WO1997005105A1 (en) 1995-07-26 1997-02-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
WO1997004775A1 (en) 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
HUP9903797A3 (en) 1995-12-05 2001-08-28 Darwin Discovery Ltd Milton Ro Benzofuran carboxamides and sulphonamides, their use for producing medicaments and such medicaments
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
BR9810733A (pt) 1997-04-04 2000-09-12 Pfizer Prod Inc Derivados de nicotinamida
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US6740655B2 (en) 2000-01-31 2004-05-25 Pfizer Inc Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
EA004885B1 (ru) 2000-01-31 2004-08-26 Пфайзер Продактс Инк. Никотинамидные бензоконденсированные гетероциклические производные, полезные в качестве селективных ингибиторов pde4-изозимов
PT1379525E (pt) 2001-02-21 2007-12-04 Astrazeneca Ab Compostos heteropolicíclicos e sua utilização como antagonistas dos receptores metabotrópicos de glutamato
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
CA2637245A1 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of tnf.alpha., pde4 and b-raf, compositions thereof and methods of use therewith
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Also Published As

Publication number Publication date
WO2010069504A1 (en) 2010-06-24
EP2196465A1 (en) 2010-06-16
TW201026681A (en) 2010-07-16
UY32239A (es) 2010-05-31

Similar Documents

Publication Publication Date Title
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CO6741198A2 (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
NI201000011A (es) Derivados de pirimidina 934.
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR091176A1 (es) Pirrodilina-2-carboxamidas sustituidas
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR057728A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
AR066873A1 (es) Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b

Legal Events

Date Code Title Description
FB Suspension of granting procedure